MedTrace Logo

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Conditions

  • Solid Tumor and Hematologic Malignancies

Interventions

DRUG

MEK162

MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-10
Primary Completion
2015-10-01
Completion
2017-04-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885195 on ClinicalTrials.gov